]>
IRCT20210129050168N1 IRCT 2022-05-30 Oroumia University of Medical Sciences Comparison of the effectiveness of morphine and ketorolac in the treatment of acute migraine attacks Comparison of the effectiveness of morphine and ketorolac in the treatment of acute migraine attacks in patients referred to emergency department of imam khomeyni hospital of urmia 2022-05-21 anticipated 70 Complete https://irct.ir/trial/54679 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: To randomize the study, the two drugs are filled into syringes marked with codes (a) for ketorolac and (b) for morphine so that the patient and the researcher are blind to the grouping of patients. The patient will be randomly placed in one of these two groups and will receive the drug and the questionnaires will be filled out while the patient and the researcher do not know about the prescribed medication, Blinding description: Participants in the project, adviser and researcher will be blind to the drug used during treatment.But the doctor will be aware of the drug. The drugs will be filled in similar syringes and in 2 boxes (a) and (b) Only the relevant doctor will be aware of. After the drug injection,the questionnaires will be filled while the patient and the researcher do not know the type of medicine. 3 acute migraine attack. Intervention 1: Intervention group: Ketorolac will be injected intravenously as a single 30 mg dose. Intervention 2: Intervention group: morphine will be injected intravenously as a single 5 mg dose. Intervention 3: Intervention group: Sumatriptan will be injected subcutaneously and in a single dose of 6 mg. Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is no
public Mostafa Chenari
Sarbazshahid
Tabriz Iran (Islamic Republic of) 5143749491 +98 935 967 2989 mostafachenari@gmail.com Oroumia University of Medical Sciences scientific Hamdollah Sharifi
Urmia
Urmia Iran (Islamic Republic of) 5756115327 +98 44 4992 3275 sharifi_md1992@yahoo.com Oroumia University of Medical Sciences Iran (Islamic Republic of) being at least 18 years old having a migraine history for at least 1 year having 2 -10 migraine attacks per month if the patient is receiving a prophylactic medication, they shouldn't have changed or interrupted it at least for the previous 3 months 18 years no limit Both The patient is allergic to the studied drugs Contraindications to the use of these drugs such as basilar migraine(migraine with brainstem aura) and hemiplegic migraine, cerebrovascular and cardiovascular diseases, uncontrolled hypertension, ergotamine-containing drugs and monoamine oxidase inhibitors Blood dyscrasias Chronic painful diseases other than migraine Chronic hepatic, renal, and pulmonary failure Drug addiction Pregnancy Type 1 and 2 diabetes G43 Migraine Treatment - Drugs Treatment - Drugs Treatment - Drugs Intervention group: Ketorolac will be injected intravenously as a single 30 mg dose Intervention group: morphine will be injected intravenously as a single 5 mg dose Intervention group: Sumatriptan will be injected subcutaneously and in a single dose of 6 mg The effect of medication on reducing pain intensity based on visual analog scale (VAS) questionnaire. Timepoint: 0 minutes- 60 minutes -120 minutes. Method of measurement: Ten-point VAS questionnaire based on pain intensity. Effects of headache on a person's quality of life and daily activities, and a score above 50 is nominated as a candidate for migraine. Timepoint: 0 minutes- 60 minutes -120 minutes. Method of measurement: A standard questionnaire to assess demographic characteristics and headache, including disability (test [HIT] -6). Oroumia University of Medical Sciences Approved 2020-09-15 Ethics committee of Urmia university of medical sciences Resalat Urmia East Azarbaijan Iran (Islamic Republic of)